Amgen claims that Vectibix, in conjuction with chemotherapy, offers an an important treatment option for patients with wild-type KRAS mCRC.
Accoding to the company, the results from the studies 20050203 (PRIME) and 20050181 (181) demonstrated that adding Vectibix to Folfox and Folfiri chemotherapy, showed improved progression-free survival (PFS) versus chemotherapy alone in patients with wild-type KRAS mCRC.
The trials proved that the patients taking this combination have a greater chance of living longer without their disease getting worse.